Matt Hitchings

Matt Hitchings,

Assistant Professor

Department: PHHP-COM BIOSTATISTICS
Business Phone: (352) 294-1945
Business Email: mhitchings@ufl.edu

Teaching Profile

Courses Taught
2021-2022
PHC6059 Introduction to Applied Survival Analysis
2023
PHC6937 Special Topics in Public Health
2023
PHC6905 Independent Study
2023
PHC7979 Advanced Research

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-2327-3557

Areas of Interest
  • Clinical Trials Design & Analysis
  • Emerging infectious disease
  • Infectious Diesease
  • Vaccination

Publications

2023
A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India.
American journal of epidemiology. 192(9):1552-1561 [DOI] 10.1093/aje/kwad103. [PMID] 37084085.
2023
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
Nature Communications. 14(1) [DOI] 10.1038/s41467-023-37944-5. [PMID] 37076502.
2023
Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility
The Journal of Infectious Diseases. 228(4):383-390 [DOI] 10.1093/infdis/jiad029. [PMID] 36740584.
2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Nature Communications. 14(1) [DOI] 10.1038/s41467-023-40750-8. [PMID] 37598213.
2023
Household Transmission Dynamics of Seasonal Human Coronaviruses.
The Journal of infectious diseases. 227(9):1104-1112 [DOI] 10.1093/infdis/jiac436. [PMID] 36350773.
2023
Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.
The American journal of tropical medicine and hygiene. 109(2):413-419 [DOI] 10.4269/ajtmh.23-0091. [PMID] 37308104.
2023
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness.
The Journal of infectious diseases. 227(5):663-674 [DOI] 10.1093/infdis/jiac453. [PMID] 36408616.
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
PLOS Medicine. 19(12) [DOI] 10.1371/journal.pmed.1004136. [PMID] 36454733.
2022
Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
BMJ (Clinical research ed.). 377 [DOI] 10.1136/bmj-2022-070102. [PMID] 35697361.
2022
Cost-effectiveness of monthly follow-up for the treatment of uncomplicated severe acute malnutrition: An economic evaluation of a randomized controlled trial.
PLOS global public health. 2(12) [DOI] 10.1371/journal.pgph.0001189. [PMID] 36962786.
2022
Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial
PLOS Medicine. 19(3) [DOI] 10.1371/journal.pmed.1003923. [PMID] 35231024.
2022
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Nature Communications. 13(1) [DOI] 10.1038/s41467-022-33169-0. [PMID] 36202800.
2022
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
The Lancet. Infectious diseases. 22(6):791-801 [DOI] 10.1016/S1473-3099(22)00140-2. [PMID] 35366959.
2022
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
Trials. 23(1) [DOI] 10.1186/s13063-022-05997-4. [PMID] 35236394.
2022
Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey
PLOS Medicine. 19(9) [DOI] 10.1371/journal.pmed.1004093. [PMID] 36074784.
2022
Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness.
Epidemiology (Cambridge, Mass.). 33(4):450-456 [DOI] 10.1097/EDE.0000000000001484. [PMID] 35384900.
2021
Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.
medRxiv : the preprint server for health sciences. [DOI] 10.1101/2021.12.23.21268335. [PMID] 34988559.
2021
Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States.
Nature communications. 12(1) [DOI] 10.1038/s41467-021-23865-8. [PMID] 34117244.
2021
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
Nature Communications. 12(1) [DOI] 10.1038/s41467-021-26459-6. [PMID] 34711813.
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
The Lancet Regional Health – Americas. 1 [DOI] 10.1016/j.lana.2021.100025. [PMID] 34386791.
2021
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
BMJ (Clinical research ed.). 374 [DOI] 10.1136/bmj.n2015. [PMID] 34417194.
2021
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(11):e4428-e4432 [DOI] 10.1093/cid/ciaa900. [PMID] 32645144.
2021
The Usefulness of the Test-Positive Proportion of Severe Acute Respiratory Syndrome Coronavirus 2 as a Surveillance Tool.
American journal of epidemiology. 190(7):1396-1405 [DOI] 10.1093/aje/kwab023. [PMID] 33576387.
2020
A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.
Vaccine. 38(51):8161-8166 [DOI] 10.1016/j.vaccine.2020.10.079. [PMID] 33162202.
2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-18450-4. [PMID] 32943637.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine. 38(46):7213-7216 [DOI] 10.1016/j.vaccine.2020.09.031. [PMID] 33012602.
2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Vaccine. 38(31):4877-4884 [DOI] 10.1016/j.vaccine.2020.04.066. [PMID] 32499066.
2019
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
PLOS Neglected Tropical Diseases. 13(3) [DOI] 10.1371/journal.pntd.0007077. [PMID] 30856166.
2019
Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.
American journal of epidemiology. 188(2):467-474 [DOI] 10.1093/aje/kwy239. [PMID] 30329134.
2019
Linear growth faltering and the role of weight attainment: Prospective analysis of young children recovering from severe wasting in Niger
Maternal & Child Nutrition. 15(4) [DOI] 10.1111/mcn.12817. [PMID] 30903806.
2018
Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.
American journal of epidemiology. 187(8):1763-1771 [DOI] 10.1093/aje/kwy047. [PMID] 29522080.
2018
Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
Clinical trials (London, England). 15(2):207-211 [DOI] 10.1177/1740774517752671. [PMID] 29374974.
2018
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial
PLOS Medicine. 15(6) [DOI] 10.1371/journal.pmed.1002593. [PMID] 29944651.
2017
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
Trials. 18(1) [DOI] 10.1186/s13063-017-2028-y. [PMID] 28646924.
2017
Using simulation to aid trial design: Ring-vaccination trials.
PLoS neglected tropical diseases. 11(3) [DOI] 10.1371/journal.pntd.0005470. [PMID] 28328984.

Grants

Apr 2022 ACTIVE
RAPID: Statistical inference of incidence of SARS-CoV-2 in the US using multiple data streams to identify levels of immunity and the impact of non-pharmaceutical interventions
Role: Co-Project Director/Principal Investigator
Funding: NATL SCIENCE FOU
Mar 2022 ACTIVE
Estimating the incidence of dengue in travelers from non-endemic countries
Role: Co-Investigator
Funding: Merck Sharp & Dohme
Jan 2022 ACTIVE
IPA for Matthew Hitchings 2022
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2021 – Jul 2023
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NIAID
May 2020 ACTIVE
Forecasting trajectories of HIV transmission networks with a novel phylodynamic and deep learning framework
Role: Project Manager
Funding: NATL INST OF HLTH NIAID

Contact Details

Phones:
Business:
(352) 294-1945
Emails:
Business:
mhitchings@ufl.edu
Addresses:
Business Mailing:
PO BOX 117450
GAINESVILLE FL 326117450